BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Boisen MK, Holst CB, Consalvo N, Chinot OL, Johansen JS. Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial. Oncotarget 2018;9:6752-62. [PMID: 29467925 DOI: 10.18632/oncotarget.22886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
2 Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One. 2013;8:e67059. [PMID: 23840582 DOI: 10.1371/journal.pone.0067059] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
3 Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 Like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201. [PMID: 32929074 DOI: 10.1038/s41392-020-00303-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
4 Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, Garcia-Esparcia P, Schmitz M, Ozbay D, Correia S, Correia Â, Milosevic I, Andréoletti O, Fernández-Borges N, Vorberg IM, Glatzel M, Sklaviadis T, Torres JM, Krasemann S, Sánchez-Valle R, Ferrer I, Zerr I. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener 2017;12:83. [PMID: 29126445 DOI: 10.1186/s13024-017-0226-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 13.4] [Reference Citation Analysis]
5 Böckelmann LC, Felix T, Calabrò S, Schumacher U. YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models. Cell Oncol (Dordr) 2021;44:1183-95. [PMID: 34432260 DOI: 10.1007/s13402-021-00630-z] [Reference Citation Analysis]
6 Boisen MK, Madsen CV, Dehlendorff C, Jakobsen A, Johansen JS, Steffensen KD. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. Int J Gynecol Cancer 2016;26:1390-8. [DOI: 10.1097/igc.0000000000000798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
7 Ali H, Harting R, de Vries R, Ali M, Wurdinger T, Best MG. Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review. Front Oncol 2021;11:665235. [PMID: 34150629 DOI: 10.3389/fonc.2021.665235] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Gudmundsdottir S, Lieder R, Sigurjonsson OE, Petersen PH. Chitosan leads to downregulation of YKL-40 and inflammasome activation in human macrophages. J Biomed Mater Res A 2015;103:2778-85. [PMID: 25684555 DOI: 10.1002/jbm.a.35417] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
9 Tan H, Yao H, Lie Z, Chen G, Lin S, Zhang Y. MicroRNA‑30a‑5p promotes proliferation and inhibits apoptosis of human pulmonary artery endothelial cells under hypoxia by targeting YKL‑40. Mol Med Rep 2019;20:236-44. [PMID: 31115541 DOI: 10.3892/mmr.2019.10251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
10 Shahy EM, Taha MM, Ibrahim KS. Assessment of YKL-40, lipid profile, antioxidant status, and some trace elements in benign and malignant breast proliferation. Mol Biol Rep 2020;47:6973-82. [PMID: 32876843 DOI: 10.1007/s11033-020-05756-1] [Reference Citation Analysis]
11 Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. PLoS One 2014;9:e87746. [PMID: 24498368 DOI: 10.1371/journal.pone.0087746] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
12 Fuksiewicz M, Kotowicz B, Rutkowski A, Achinger-Kawecka J, Wagrodzki M, Kowalska MM. The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis. Technol Cancer Res Treat 2018;17:1533033818765209. [PMID: 29642772 DOI: 10.1177/1533033818765209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Karagiannis P, Fittall M, Karagiannis SN. Evaluating biomarkers in melanoma. Front Oncol 2014;4:383. [PMID: 25667918 DOI: 10.3389/fonc.2014.00383] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
14 Thongsom S, Chaocharoen W, Silsirivanit A, Wongkham S, Sripa B, Choe H, Suginta W, Talabnin C. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Tumour Biol. 2016;37:9451-9463. [PMID: 26781979 DOI: 10.1007/s13277-016-4838-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
15 Wang Y, Wong CW, Yan M, Li L, Liu T, Or PM, Tsui SK, Waye MM, Chan AM. Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/Phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma. Cancer Lett 2018;429:54-65. [PMID: 29729901 DOI: 10.1016/j.canlet.2018.04.040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
16 Nielsen TL, Plesner LL, Warming PE, Pallisgaard JL, Dalsgaard M, Schou M, Høst U, Rydahl C, Brandi L, Køber L, Johansen JS, Kastrup J, Iversen KK. YKL-40 in patients with end-stage renal disease receiving haemodialysis. Biomarkers 2018;23:357-63. [DOI: 10.1080/1354750x.2018.1428359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
17 Zhao Y, Zhang Y, Zhang J, Yang G. Plasma proteome profiling using tandem mass tag labeling technology reveals potential biomarkers for Parkinson's disease: a preliminary study. Proteomics Clin Appl 2021;:e2100010. [PMID: 34791804 DOI: 10.1002/prca.202100010] [Reference Citation Analysis]
18 Kwak SY, Seo IH, Chung I, Kim SA, Lee JO, Lee HJ, Kim SE, Han JA, Kang MJ, Kim SJ, Lim S, Kim KM, Chung JH, Lim E, Hwang JI, Kim HS, Shin MJ. Effect of chitinase-3-like protein 1 on glucose metabolism: In vitro skeletal muscle and human genetic association study. FASEB J 2020;34:13445-60. [PMID: 32816366 DOI: 10.1096/fj.202000925R] [Reference Citation Analysis]
19 Lee JW, Kim MN, Kim EG, Leem JS, Baek SM, Kim MJ, Kim KW, Sohn MH. Chitinase 3-like 1 is involved in the induction of IL-8 expression by double-stranded RNA in airway epithelial cells. Biochem Biophys Res Commun 2022;592:106-12. [PMID: 35033868 DOI: 10.1016/j.bbrc.2022.01.008] [Reference Citation Analysis]
20 Rivas-Alarcón AA, Gómez-Gómez Y, Organista-Nava J, Jiménez-López MA, Rivera-Ramírez AB, Ibarra-Sierra E, Saavedra-Herrera MV, Illades-Aguiar B, Leyva-Vázquez MA. Plasma levels of YKL-40 as a prognostic factor in childhood acute lymphoblastic leukemia. Mol Clin Oncol 2021;15:168. [PMID: 34194746 DOI: 10.3892/mco.2021.2330] [Reference Citation Analysis]
21 Brøchner CB, Johansen JS, Larsen LA, Bak M, Mikkelsen HB, Byskov AG, Andersen CY, Møllgård K. YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem 2012;60:188-204. [PMID: 22140133 DOI: 10.1369/0022155411433331] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
22 Hansen JW, Thomsen SF, Porsbjerg C, Rasmussen LM, Harmsen L, Johansen JS, Backer V. YKL-40 and genetic status of CHI3L1 in a large group of asthmatics. Eur Clin Respir J 2015;2:25117. [PMID: 26672955 DOI: 10.3402/ecrj.v2.25117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
23 Senetta R, Duregon E, Sonetto C, Spadi R, Mistrangelo M, Racca P, Chiusa L, Munoz FH, Ricardi U, Arezzo A, Cassenti A, Castellano I, Papotti M, Morino M, Risio M, Cassoni P. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study. PLoS One 2015;10:e0123759. [PMID: 25875173 DOI: 10.1371/journal.pone.0123759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
24 Linhares P, Carvalho B, Vaz R, Costa BM. Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance? Int J Mol Sci 2020;21:E5809. [PMID: 32823572 DOI: 10.3390/ijms21165809] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
25 Harutyunyan M, Johansen JS, Mygind ND, Reuter SB, Kastrup J. Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease. Biomark Med 2014;8:977-87. [PMID: 25343670 DOI: 10.2217/bmm.14.20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Farias FHG, Benitez BA, Cruchaga C. Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. Neurobiol Dis 2021;151:105247. [PMID: 33429041 DOI: 10.1016/j.nbd.2020.105247] [Reference Citation Analysis]
27 Cavaco A, Rezaei M, Niland S, Eble JA. Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy. Int J Mol Sci 2017;18:E2355. [PMID: 29112161 DOI: 10.3390/ijms18112355] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
28 Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol 2014;31:85. [PMID: 24996799 DOI: 10.1007/s12032-014-0085-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
29 Szymańska-Chabowska A, Juzwiszyn J, Jankowska-Polańska B, Tański W, Chabowski M. Chitinase 3-Like 1, Nestin, and Testin Proteins as Novel Biomarkers of Potential Clinical Use in Colorectal Cancer: A Review. Adv Exp Med Biol 2020;1279:1-8. [PMID: 32170669 DOI: 10.1007/5584_2020_506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Furukawa T, Matsui K, Kitano M, Yokoyama Y, Sekiguchi M, Azuma N, Imai Y, Hirota S, Yamanishi K, Sano H. Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis. Modern Rheumatology 2019;29:476-83. [DOI: 10.1080/14397595.2018.1480256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gil-Perotin S, Castillo-Villalba J, Cubas-Nuñez L, Gasque R, Hervas D, Gomez-Mateu J, Alcala C, Perez-Miralles F, Gascon F, Dominguez JA, Casanova B. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. Front Neurol 2019;10:1008. [PMID: 31608004 DOI: 10.3389/fneur.2019.01008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
32 Mygind ND, Axelsson A, Ruwald MH, Dalsgaard M, Steffensen R, Iversen K, Johansen JS, Kastrup J. The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test. Cardiovasc Endocrinol 2016;5:21-7. [PMID: 28392973 DOI: 10.1097/XCE.0000000000000073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Mistrangelo M, Senetta R, Racca P, Castellano I, Chiusa L, Bellò M, Ricardi U, Morino M, Cassoni P. A novel biomarker-based analysis reliably predicts nodal metastases in anal carcinoma: preliminary evidence of therapeutic impact. Colorectal Dis 2013;15:1382-91. [PMID: 23692332 DOI: 10.1111/codi.12289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
34 Oh IH, Pyo JS, Son BK. Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer. Curr Oncol 2021;28:3139-49. [PMID: 34436040 DOI: 10.3390/curroncol28040274] [Reference Citation Analysis]
35 Mygind ND, Iversen K, Køber L, Goetze JP, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V, Kastrup J. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. J Intern Med 2013;273:205-16. [PMID: 23140269 DOI: 10.1111/joim.12006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
36 Kjaergaard AD, Bojesen SE, Nordestgaard BG, Johansen JS. YKL-40 and alcoholic liver and pancreas damage and disease in 86,258 individuals from the general population: cohort and mendelian randomization studies. Clin Chem 2014;60:1429-40. [PMID: 25225167 DOI: 10.1373/clinchem.2014.229096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
37 Chaocharoen W, Schulte A, Suginta W. hYKL-40 cancer biomarker electroanalysis in serum samples and model cell lysates: capacitive immunosensing compared with enzyme label immunosorbent assays (ELISA). Analyst 2017;142:503-10. [DOI: 10.1039/c6an02239a] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
38 Pouyafar A, Heydarabad MZ, Mahboob S, Mokhtarzadeh A, Rahbarghazi R. Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed Pharmacother 2018;100:478-85. [PMID: 29477911 DOI: 10.1016/j.biopha.2018.02.050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
39 Jin X, Fu B, Wu ZJ, Zheng XQ, Hu JH, Jin LF, Tang LL. Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China. Hepatobiliary Pancreat Dis Int 2020;19:384-9. [PMID: 32540209 DOI: 10.1016/j.hbpd.2020.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]